Trevena (TRVN) To Post Q1 Earnings: What Awaits The Stock?
Zacks Investment Research | Apr 23, 2019 11:43PM ET
Investor focus will be on Trevena, Inc.’s (NASDAQ:TRVN) efforts to support the development of its pain therapy, oliceridine injection, when the company reports first-quarter 2019 earnings.
Trevena’s performance over the last four quarters has been encouraging so far with the company’s earnings surpassing expectations thrice and missing the mark just once. The average positive surprise over the trailing four quarters is 3.38%. In the last reported quarter, Trevena came up with a negative earnings surprise of 66.67%.
Shares of Trevena have skyrocketed 239.5% in the year so far, outperforming the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.